At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $481.59, up 1.19%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ALNY shares have gain 3.59% over the last week, with a monthly amount glided 5.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on August 04, 2025, when Wolfe Research upgraded its rating to a Peer Perform. Previously, Oppenheimer upgraded its rating to Outperform on August 04, 2025, and kept the price target unchanged to $490. Truist started tracking the stock assigning a Buy rating and suggested a price target of $385 on July 21, 2025. Redburn Atlantic initiated its recommendation with a Buy and recommended $353 as its price target on March 31, 2025. JP Morgan upgraded its rating to Overweight for this stock on March 24, 2025, and upped its price target to $328. In a note dated November 12, 2024, Wolfe Research downgraded an Underperform rating on this stock.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $205.87 and $495.55. Currently, Wall Street analysts expect the stock to reach $465.83 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $481.59 at the most recent close of the market. An investor can expect a potential drop of -3.27% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.46B for trailing twelve months, which represents an 17.26% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -2.74 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of5.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 471.54 points at the first support level, and at 461.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 487.18, and for the 2nd resistance point, it is at 492.78.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 2.80. Also, the Quick Ratio is 2.75, while the Cash Ratio stands at 0.86. Considering the valuation of this stock, the price to sales ratio is 25.64, the price to book ratio is 251.71.
Transactions by insiders
Recent insider trading involved Poulton Jeffrey V., EVP, Chief Financial Officer, that happened on Oct 02 ’25 when 3821.0 shares were sold. Chief Executive Officer, Greenstreet Yvonne completed a deal on Oct 02 ’25 to sell 8924.0 shares. Meanwhile, EVP, Chief Commercial Officer Tanguler Tolga sold 1405.0 shares on Oct 02 ’25.
